Product
Tafamidis
Aliases
Tafamidis 61 mg free acid capsule (Reference), Tafamidis 61 mg free acid tablet (Test 1), Tafamidis 70 mg free acid tablet (Test 1)
10 clinical trials
7 indications
Indication
HealthyIndication
Transthyretin Amyloidosis CardiomyopathyIndication
Transthyretin Amyloid CardiomyopathyIndication
Hereditary Transthyretin AmyloidosisIndication
PolyneuropathyIndication
Transthyretin AmyloidosisClinical trial
A PHASE 1, OPEN-LABEL, RANDOMIZED, THREE-TREATMENT, THREE-PERIOD, CROSSOVER, SINGLE DOSE STUDY TO ESTIMATE THE RELATIVE BIOAVAILABILITY OF 61 MG AND 70 MG TAFAMIDIS FREE ACID TABLETS TO COMMERCIAL 61 MG TAFAMIDIS FREE ACID CAPSULE ADMINISTERED UNDER FASTED CONDITIONS IN HEALTHY ADULT PARTICIPANTSStatus: Active (not recruiting), Estimated PCD: 2024-05-27
Clinical trial
Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy (ATTR-CM)Status: Not yet recruiting, Estimated PCD: 2024-06-30
Clinical trial
Clinical Benefit of Tafamidis 61mg for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Patients in Korean Population in the Real-world Setting, Multicenter, Non-interventional StudyStatus: Active (not recruiting), Estimated PCD: 2025-04-30
Clinical trial
A SINGLE ARM, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF ORALLY ADMINISTERED TAFAMIDIS MEGLUMINE IN TRANSTHYRETIN AMYLOID POLYNEUROPATHY PARTICIPANTS IN CHINAStatus: Completed, Estimated PCD: 2023-02-12
Clinical trial
A Study to Characterize the Safety and Efficacy of Tafamidis Once Daily in the Treatment of Transthyretin Amyloid Cardiomyopathy in Chinese ParticipantsStatus: Completed, Estimated PCD: 2023-10-16
Clinical trial
Tafamidis 61mg, Resultados en Amiloidosis ATTR Con afectación neurológica y Multisistémica - TRAMAStatus: Completed, Estimated PCD: 2022-11-15
Clinical trial
A PHASE 1, OPEN-LABEL, RANDOMIZED, CROSSOVER, SINGLE DOSE STUDY TO ESTIMATE THE RELATIVE BIOAVAILABILITY OF VARIANT 12.2 MG TAFAMIDIS FREE ACID TABLETS AND PROPOSED COMMERCIAL 12.2 MG TAFAMIDIS FREE ACID TABLETS ADMINISTERED UNDER FASTED CONDITIONS IN HEALTHY ADULT PARTICIPANTSStatus: Completed, Estimated PCD: 2022-10-28
Clinical trial
An Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart TransplantationStatus: Recruiting, Estimated PCD: 2025-04-30
Clinical trial
A PHASE 3 MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826-83) 20 MG OR 80 MG [OR TAFAMIDIS (PF-06291826-00) 61 MG] IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (ATTR-CM)Status: Completed, Estimated PCD: 2023-10-26
Clinical trial
A Prospective, Single-arm, Multicenter, Observational Safety Surveillance Study of VyndaMx® (Tafamidis Capsule 61 mg) in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in IndiaStatus: Recruiting, Estimated PCD: 2025-04-30